Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2016/09/29 – Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2016/09/22 – Quantum Genomics Announces Conference Call to Review Top-line Results from Phase IIa Study of QGC001 in Hypertension
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2016/09/12 – Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2016/09/06 – Quantum Genomics to Present at Rodman & Renshaw 18th Annual Conference in New York on September 13
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2016/06/30 – Quantum Genomics initiates Phase IIa trial for Heart Failure, the second strategic initiative for its BAPAI therapeutic platform
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2016/06/28 – Quantum Genomics extends its collaboration agreement with its partner in animal health
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2016/05/31 – Quantum Genomics symposium at the European Meeting on Hypertension and Cardiovascular Protection
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2016/05/17 – Quantum Genomics granted two new U.S. patents covering lead product QGC001
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…
2016/04/26 – Regulatory authorisations received in France to begin Phase IIa multicentric European trial for heart failure
Quantum Genomics (Alternext – FR0011648971 – ALQGC), a biopharmaceutical company with the mission of developing new…